SEARCH

SEARCH BY CITATION

References

  • 1
    Compalati E, Penagos M, Henley K, Canonica GW. Allergy Prevalence Survey by the World Allergy Organization. Allergy Clin Immunol Int–J World Allergy Org 2007;19:8290.
  • 2
    Asher MI. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368:733743.
  • 3
    Prenner BM, Schenkel E. Allergic rhinitis: treatment based on patient profiles. Am J Med 2006;119:230237.
  • 4
    Van Drunen C, Meltzer EO, Bachert C, Bousquet J, Fokkens WJ. Nasal allergies and beyond: a clinical review of the pharmacology, efficacy, and safety of mometasone furoate. Allergy 2005;60:S5S19.
  • 5
    Bousquet J. Allergic rhinitis and its impact on asthma (ARIA). Clin Exp All Rev 2003;3:4345.
  • 6
    Brozek JL, Baena-Cagnani C, Bonini S, Canonica GW, Rasi G, Van Wijk RG. Methodology for development of the Allergic Rhinitis and its Impact on Asthma Guideline 2007 update. Allergy 2008;63:3846.
  • 7
    Canonica GW, Tarantini F, Compalati E, Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy 2007;62:359366.
  • 8
    Scadding GK, Durham SR, Mirakian R, Jones NS, Leech SC, Farooque S et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008;38:1942.
  • 9
    Bousquet J, Van Cauwenberge P. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S146S150.
  • 10
    Plaut M, Valentine MD. Allergic rhinitis. N Engl J Med 2005;353:19341944.
  • 11
    Van Cauwenberge P. Consensus statement* on the treatment of allergic rhinitis. Allergy 2000;55:116134.
  • 12
    Lundblad L, Sipilä P, Farstad T, Drozdziewicz D. Mometasone furoate nasal spray in the treatment of perennial non-allergic rhinitis: a nordic, multicenter, randomized, double-blind, placebo-controlled study. Acta Otolaryngol 2001;121:505509.
  • 13
    Stjarne P, Blomgren K, Caye-Thomasen P, Salo S, Soderstrom T. The efficacy and safety of once-daily mometasone furoate nasal spray in nasal polyposis: a randomized, double-blind, placebo-controlled study. Acta Otolaryngol 2006;126:606612.
  • 14
    Small CB, Hernandez J, Reyes A, Schenkel E, Damiano A, Stryszak P et al. Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. J Allergy Clin Immunol 2005;116:12751281.
  • 15
    Berlucchi M, Salsi D, Valetti L, Parrinello G, Nicolai P. The role of mometasone furoate aqueous nasal spray in the treatment of adenoidal hypertrophy in the pediatric age group: preliminary results of a prospective, randomized study. Pediatrics 2007;119:e1392e1397.
  • 16
    Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol 2005;116:12891295.
  • 17
    Barnes ML, Biallosterski BT, Fujihara S, Gray RD, Fardon TC, Lipworth BJ. Effects of intranasal corticosteroid on nasal adenosine monophosphate challenge in persistent allergic rhinitis. Allergy 2006;61:13191325.
  • 18
    Hebert JR, Nolop K, Lutsky BN. Once-daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: an active- and placebo-controlled study. Allergy 1996;51:569576.
  • 19
    Meltzer EO, Jalowayski AA, Orgel HA, Harris AG. Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray. J Allergy Clin Immunol 1998;102:3949.
  • 20
    Graft D, Aaronson D, Chervinsky P, Kaiser H, Melamed J, Pedinoff A et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol 1996;98:724731.
  • 21
    Mandl M, Nolop K, Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. 194-079 Study Group. Ann Allergy Asthma Immunol 1997;79:370378.
  • 22
    Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf 2007;30:317326.
  • 23
    Cutler DL, Banfield C, Affrime MB. Safety of mometasone furoate nasal spray in children with allergic rhinitis as young as 2 years of age: a randomized controlled trial. Pediatr Asthma Allergy Immunol 2006;19:146153.
  • 24
    Meltzer EO, Berger WE, Berkowitz RB, Bronsky EA, Dvorin DJ, Finn AF et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104:107114.
  • 25
    Brannan MD, Seiberling M, Cutler DL, Cuss FM, Affrime MB. Lack of systemic activity with intranasal mometasone furoate. J Allergy Clin Immunol 1996;97:198204.
  • 26
    Schenkel E, Skoner D, Bronsky E, Miller SD, Pearlman DS, Rooklin A et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000;105:E22.
  • 27
    Minshall E, Ghaffar O, Cameron L, O’Brien F, Quinn H, Rowe-Jones J et al. Assessment by nasal biopsy of long-time use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 1998;118:648654.
  • 28
    Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUORUM statement. Quality of reporting meta-analysis. Lancet 1999;354:18961900.
  • 29
    HigginsJPT, GreenS (editors). Cochrane handbook for systematic reviews of interventions version 5.0.0. [Updated February 2008]. The Cochrane Collaboration, 2008. Available from http://www.cochrane-handbook.org.
  • 30
    Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002;31:150153.
  • 31
    Dawson B. Research questions about one group. In: DawsonB, editor. Basic & clinical biostatistics, 4th edn. New York: McGraw-Hill Medical, 2004:118.
  • 32
    Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med 2005;37:360363.
  • 33
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:112.
  • 34
    Moher D, Cook DJ, Jadad AR, Tugwell P, Moher M, Jones A et al. Assessing the quality of randomized controlled trials: implications for the conduct of meta-analyses. Health Technol Assess 1999;3:No. 12.
  • 35
    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307310.
  • 36
    MedCalc for Windows, Version 8.1.1 [Computer program]. Mariakerke: MedCalc Software, 2006.
  • 37
    Plot Digitizer 2.4.1 Program [Computer program]. Kansas, 2003.
  • 38
    Spector SL, Nicklas RA, Chapman JA, Bernstein IL, Berger WE, Blessing-Moore J et al. Symptom severity assessment of allergic rhinitis: part 1. Ann Allergy Asthma Immunol 2003;91:105114.
  • 39
    Deeks JJ, Altman D, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: EggerM, Davey SmithG, AltmanDG, editors. Systematic reviews in health care. London: BMJ Publishing, 2001:285312.
  • 40
    Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997;315:15331537.
  • 41
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557560.
  • 42
    Sutton AJ, Higgins JP. Recent developments in meta-analysis. Stat Med 2008;27:625650.
  • 43
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177188.
  • 44
    DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007;28:105114.
  • 45
    Wang MC, Bushman BJ. Using the normal quantile plot to explore meta-analytic data sets. Psychol Methods 1998;3:4654.
  • 46
    Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A et al. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008;133:599609.
  • 47
    RevMan Analyses Version 5.0 for Windows [Computer program]. Oxford: The Cochrane Collaboration, 2008.
  • 48
    SPSS Version 14.0 for Windows [Computer program]. Chicago, IL: SPSS Inc, 2007.
  • 49
    Bronsky EA, Aaronson DW, Berkowitz RB, Chervinsky P, Graft D, Kaiser HB et al. Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:5156.
  • 50
    Bende M, Carrillo T, Vóna I, Da Castel-Branco MG, Arheden L. A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. Ann Allergy Asthma Immunol 2002;88:617623.
  • 51
    Drouin M, Yang WH, Bertrand B, Van Cauwenberge P, Clement P, Dalby K et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 1996;77:153160.
  • 52
    Berkowitz RB, Bernstein DI, LaForce C, Pedinoff AJ, Rooklin AR, Damaraju CR et al. Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy 1999;54:6469.
  • 53
    Stuck BA, Blum A, Hagner AE, Hummel T, Klimek L, Hörmann K. Mometasone furoate nasal spray improves olfactory performance in seasonal allergic rhinitis. Allergy 2003;58:1195.
  • 54
    Gawchik S, Goldstein S, Prenner B, John A. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann Allergy Asthma Immunol 2003;90:416421.
  • 55
    Ciprandi G, Tosca MA, Passalacqua G, Canonica GW. Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge. Ann Allergy Asthma Immunol 2001;86:433438.
  • 56
    Frieri M, Therattil J, Chavarria V, Cosachov J, Kumar NS, Wang SF et al. Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1998;81:431437.
  • 57
    Patel P, D’Andrea C, Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol 2007;21:499503.
  • 58
    Berkowitz RB, Roberson S, Zora J, Capano D, Chen R, Lutz C et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc 1999;20:167172.
  • 59
    Higgins J, Thompson S, Deeks J, Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002;7:5161.
  • 60
    Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002;89:479484.
  • 61
    Weiner JM, Abrahamson MJ, Puy RM. Intranasal corticosteroids versus H1 receptor antagonists in allergic rhinitis: systemic review of randomized controlled trials. Br Med J 1998;317:16241630.
  • 62
    Wihl JA, Petersen BN, Petersen LN, Gundersen G, Bresson G, Mygind N. Effect of the nonsedative H1-receptor antagonist astemizole in perennial allergic and nonallergic rhinitis. J Allergy Clin Immunol 1985;75:720727.
  • 63
    Pullerits T, Praks L, Ristioja V, Lotvall J. Comparison of nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109:949955.
  • 64
    Sussman G, Danzig M, Gates D. Total ocular symptom scores in patients with seasonal allergic rhinitis are reduced with mometasone furoate nasal spray. J Allergy Clin Immunol 2007;119:S61 [Abstract].
  • 65
    Cohen J. Statistical power analysis for the behavioral sciences, 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
  • 66
    Sterne JAC, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001;54:10461055.
  • 67
    Laczo RM, Sackett PR, Bobko P, Cortina JM. A comment on sampling error in the standardized mean difference with unequal sample sizes: avoiding potential errors in meta-analytic and primary research. J Appl Psychol 2005;90:758764.
  • 68
    Berger WE, Nayak AS, Staudinger HW. Mometasone furoate improves congestion in patients with moderate-to-severe seasonal allergic rhinitis. Ann Pharmacother 2005;39:19841989.
  • 69
    Camara-Clark OA, Araujo-Castro A. Searching the Literatura Latino Americana e do Caribe em Ciências da Saúde (LILACS) database improves systematic reviews. Int J Epidemiol 2002;31:112114.
  • 70
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629634.